Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신윤용 | * |
dc.contributor.author | 김대기 | * |
dc.date.accessioned | 2016-08-29T12:08:56Z | - |
dc.date.available | 2016-08-29T12:08:56Z | - |
dc.date.issued | 2016 | * |
dc.identifier.issn | 1015-8987 | * |
dc.identifier.other | OAK-18812 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/231645 | - |
dc.description.abstract | Background/Aims: Hypoxia is an environmental factor that aggravates liver fibrosis. HIFla activates hepatic stellate cells (HSCs) and increases transforming growth factor-ß (TGF-β) signaling and the epithelial mesenchymal transition (EMT), accelerating the progression of fibrosis. We evaluated the anti-fibrotic therapeutic potential of a small-molecule inhibitor of TGF-β type I receptor kinase, EW-7197, on HIF1α-derived TGF-β signaling in cholestatic liver fibrosis. Methods: We used a bile duct ligation (BDL)-operated rat model to characterize the role of HIF1α-derived TGF-β signaling in liver fibrosis. Cellular assays were performed in LX-2 cells (human immortalized HSCs). The anti-fibrotic effects of EW-7197 in livertissues and HSCs were investigated via biochemical assays, immunohistochemistry (IHC), immunofiuorescence (IF), chromatin immunoprecipitation (ChIP) assays, real-time PCR, and western blotting. Results: In our BDL rat model, orally administered EW-7197 inhibited fibrosis and attenuated HIF1α-induced activation of HSCs and EMT in vivo. In addition, EW-7197 inhibited HIF1α-derived HSC activation and expression of EMT markers in LX-2 cells in vitro. Conclusion: This study suggests that EW-7197 exhibits potential as a treatment for liver fibrosis because it inhibits HIF1α-induced TGF-β signaling. © 2016 The Author(s). | * |
dc.language | English | * |
dc.publisher | S. Karger AG | * |
dc.subject | Cholestatic liver injury | * |
dc.subject | Epithelial mesenchymal transition | * |
dc.subject | EW-71/7 | * |
dc.subject | Hepatic stellate cell | * |
dc.subject | HIFlα | * |
dc.subject | TGF-β | * |
dc.title | TGF-β type i receptor kinase inhibitor EW-7197 suppresses cholestatic liver fibrosis by inhibiting HIF1α-induced epithelial mesenchymal transition | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 38 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 571 | * |
dc.relation.lastpage | 588 | * |
dc.relation.journaltitle | Cellular Physiology and Biochemistry | * |
dc.identifier.doi | 10.1159/0000438651 | * |
dc.identifier.scopusid | 2-s2.0-84971595292 | * |
dc.author.google | Kim M.-J. | * |
dc.author.google | Park S.-A. | * |
dc.author.google | Kim C.H. | * |
dc.author.google | Park S.-Y. | * |
dc.author.google | Kim J.-S. | * |
dc.author.google | Kim D.-K. | * |
dc.author.google | Nam J.-S. | * |
dc.author.google | Sheen Y.Y. | * |
dc.contributor.scopusid | 신윤용(6603872711) | * |
dc.contributor.scopusid | 김대기(35083694200) | * |
dc.date.modifydate | 20240118164500 | * |